NEW YORK (GenomeWeb News) – Arrayit Diagnostics said today that it has exclusively licensed ovarian cancer biomarker intellectual property from Wayne State University.

Under the agreement, Houston-based Arrayit Diagnostics, a majority-owned subsidiary of Sunnyvale, Calif.-based Arrayit Corporation, gains exclusive worldwide rights to develop and commercialize a microarray-based diagnostic test using the biomarkers, which were developed by WSU researchers Michael Tainsky, Sorin Draghici, and Madhumita Chatterjee.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: researchers classify pancreatic cancer into four subtypes using sequencing, and more.

Genotyping analysis of measles in Ontario indicates the strain there didn't originate from Disneyland or Europe.

The UK Medical Research Council says the proposed path of a new train line could affect research at the Francis Crick Institute.

The House of Lords in the UK approves a bill to allow mitochondrial donation.